[Research on Insufficient Information for Pharmaceutical Products]

Area of Science:

• Pharmacology
• Drug Safety
• Risk Management

Background:

• Information regarding drug side effects and risks is often not readily available or recognizable.
• Package inserts are a key source of drug information but may contain incomplete risk data.

Purpose of the Study:

• To evaluate the mechanisms of drug side effects.
• To assess the completeness of risk indications in medicine package inserts.
• To identify gaps in drug safety information provided to healthcare professionals and patients.

Main Methods:

• Review of scientific literature on drug side effect mechanisms.
• Analysis of package insert content for specific drugs, including gatifloxacin.
• Evaluation of the association between drug components (e.g., polysorbate) and elution of plasticizers (e.g., DEHP).
• Assessment of risk management strategies and pharmacovigilance data reporting.

Main Results:

• Gatifloxacin exposure can significantly alter insulin secretion and islet cell function, with prolonged exposure leading to greater insulin depletion than other fluoroquinolones.
• Elution of di(2-ethylhexyl)phthalate (DEHP) from infusion sets may be linked to solubilizers in injectable medicines; package inserts often lack warnings about this risk.
• A significant number of potential drug risks (56 out of 268) were not mentioned in package inserts, indicating a gap in risk communication.

Conclusions:

• There are critical deficiencies in drug safety information provided in package inserts, impacting risk assessment and management.
• Package insert content requires reevaluation and enhancement to accurately reflect drug-induced risks, such as those associated with gatifloxacin and DEHP elution.
• Improved pharmacovigilance and clearer communication of risks in package inserts are essential for patient safety.